News FDA orders blindness risk warning to GLP-1 agonist labels FDA has ordered all GLP-1 receptor agonist manufacturers to add a warning to their product labels for a rare eye condition that can cause blindness.
News GLP-1 drugs linked to reduced acute schizophrenia episodes The list of illnesses that may benefit from treatment with GLP-1 drugs gets ever longer, and a study has found that schizophrenia may be an addition.
Sales & Marketing Your launch strategy has never met the competition Will your launch strategy work once it has finally left the meeting room and met the competition?
Patients Maintenance: The underexamined half of the GLP-1 story GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.
News FDA issues warning letters to five unapproved GLP-1 websites In a handful of strongly-worded warning letters, the FDA is cracking down on sales of unapproved peptides - even if they're labelled for research.
News UK MHRA authorises orforglipron private prescription Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.